Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

01 December 2007

Therapeutic drug monitoring of ciclosporin

A. Johnston, D. W. Holt

Ann Transplant 2008; 13(1): 24-24 :: ID: 880178

Abstract

There can be no doubt that the introduction of ciclosporin for the prevention of rejection of transplanted organs, in the early nineteen eighties, revolutionised transplantation. However, the inability to define an individual's optimal ciclosporin dose, one that maximises effi cacy while at the same time minimises toxicity, has been a problem. For this reason therapeutic drug monitoring (TDM) of ciclosporin has become an established part of the routine clinical management of patients receiving the drug after organ transplantation. The use of drug concentrations as a means of optimising ciclosporin dose has evolved in a haphazard and ad hoc fashion. Initially plasma or serum blood concentrations were measured using assay techniques that were not specific for the parent compound. Over time it was realised that neither plasma nor serum were appropriate matrices as the temperature, and hence time, of separation caused major changes in the partitioning of ciclosporin into red cells. Therefore whole blood, with EDTA anticoagulation, became the matrix of choice for the measurement of the drug. At the same time, it was becoming apparent that variations in the metabolite to parent drug ratio with time after transplant, transplant type, concurrent disease and even during rejection made the use of non-specific measurements of drug concentration unreliable and a series of specific, or at least "more specific", assay methodologies were developed. Therefore measurement of ciclosporin in whole blood with a specific assay method became the agreed consensus for all transplant types. However, there is no consensus on whether for the best results a target value or range of values should be used, what the target(s) should be, how these should be adjusted to allow for transplant type, co-medication, time after transplantation, concomitant disease, race, sex etc. Added to which there is still debate about whether pre-dose (trough or C0) or another timed sample, such as two hours after drug administration (C2), or area under the concentration time-curve (AUC) result in the best patient outcomes. These questions may only be answered, and the relative merits of different sampling times decided, by prospective testing in double blind trials. Therapeutic drug monitoring, like any other medical intervention, needs to be evaluated in terms of cost-effectiveness, feasibility and clinical relevance, with the ultimate goal of improving patient and graft survival.

Keywords: thyroid cancer metestasis, Transplantation, therapeutic drug monitoring

0 Comments

In Press

04 Aug 2022 : Original article  

Long-Term Patency of All-in-One Sleeve Patch Graft Venoplasty in 16 Patients Who Underwent Living Donor Liv...

Ann Transplant In Press; DOI: 10.12659/AOT.936888  

22 Jul 2022 : Original article  

Diagnostic Role of Tumor Markers for Hepatocellular Carcinoma in Liver Transplantation Candidates: An Analy...

Ann Transplant In Press; DOI: 10.12659/AOT.936937  

22 Jul 2022 : Original article  

Development of a Novel Model for Predicting Postoperative Short-Term Outcome in Patients with Hepatitis B-R...

Ann Transplant In Press; DOI: 10.12659/AOT.936732  

22 Jul 2022 : Original article  

Leucine-Rich Alpha-2-Glycoprotein (LRG-1) as a Potential Kidney Injury Marker in Kidney Transplant Recipients

Ann Transplant In Press; DOI: 10.12659/AOT.936751  

Most Viewed Current Articles

26 Jan 2022 : Review article  

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

DOI :10.12659/AOT.934924

Ann Transplant 2022; 27:e934924

29 Dec 2021 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

24 Jul 2020 : Review article  

Kidney Transplantation in the Times of COVID-19 – A Literature Review

DOI :10.12659/AOT.925755

Ann Transplant 2020; 25:e925755

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358